AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

Rhea-AI Summary

AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Chairman of the Board Gabriele Cerrone has increased his stake in the company. Cerrone purchased an additional 2,400 shares of ACUT in the open market, bringing his total holdings to 6,502,400 shares. This insider purchase by the Chairman demonstrates leadership's confidence in the company's direction and potential.

Positive

• Chairman's increased stake signals confidence in company's future
• Significant insider ownership with Chairman holding over 6.5 million shares
• Open market purchase demonstrates management's alignment with shareholder interests

Negative

• None.

News Market Reaction – ACUT

-7.34%

-7.34% Session move

In the trading session that priced this news, ACUT declined 7.34%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. This brings his total holding to 6,502,400 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.

For more information, please visit www.accustem.com.

Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com

FAQ

How many ACUT shares did AccuStem Sciences Chairman purchase in June 2025?

AccuStem Sciences Chairman Gabriele Cerrone purchased 2,400 additional ACUT shares in the open market in June 2025.

What is the total number of shares held by AccuStem Sciences Chairman Gabriele Cerrone?

After his recent purchase, Chairman Gabriele Cerrone holds a total of 6,502,400 shares of AccuStem Sciences (ACUT).

What does the Chairman's share purchase indicate about AccuStem Sciences (ACUT)?

The Chairman's share purchase indicates insider confidence in the company's future and aligns management interests with shareholders.

What type of company is AccuStem Sciences (ACUT)?

AccuStem Sciences is a clinical stage diagnostics company focused on improving outcomes for cancer patients.